Great Novel Therapeutics Biotech & Medicals (TPEX: 7427)
Health Care · Biotechnology · TW
NT$66.10
-5.97% today · +118.9% 1Y
Great Novel Therapeutics Biotech & Medicals (TPEX: 7427) operates in the Biotechnology industry within the Health Care sector. The company is valued at $109.39M and employs 23 people.
Over the last twelve months the share price has gained 118.9%, trading between 29.25 and 82.80.
Tweenvest scores Great Novel Therapeutics Biotech & Medicals across four factors: quality 41/100, value 74/100. Its strongest factor is value.
7427 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $109.39M
- Revenue (TTM)
- $195.13K
- P/E
- —
- EPS
- -2.52
- Dividend yield
- —
- Beta (5Y)
- 0.21
- 52-week high
- NT$82.80
- 52-week low
- NT$29.25
- Avg volume (3M)
- —
- Shares outstanding
- 52.91M
- Employees
- 23
- Next earnings
- —
About Great Novel Therapeutics Biotech & Medicals
Great Novel Therapeutics Biotech & Medicals specializes in crafting pharmaceutical solutions to combat advanced and treatment-resistant cancers. Their primary focus lies in the realm of cancer immunotherapy, encompassing the creation of compounds such as tumor microenvironment regulators, epigenetic immunoactivators, and immune-regulating multi-kinase inhibitors. The company was previously known as GNT Biotech & Medicals Corporation. Established in 2013, its headquarters are situated in Taipei City, Taiwan.
- ISIN
- TW0007427007
- Founded
- 2013
- Listed since
- Jul 8, 2021
- Exchange
- Taipei Exchange
- Currency
- TWD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Hamlet BioPharma AB (publ)XSAT: HAMLET B | $113.40M | Skr6.08 | +1.50% |
| Insight Molecular Diagnostics Inc.NasdaqCM: IMDX | $110.28M | $3.06 | -9.20% |
| PDS Biotechnology CorporationNasdaqCM: PDSB | $110.16M | $1.64 | +7.89% |
| Conexeu Sciences Inc.NasdaqCM: CNXU | $109.72M | $3.33 | -14.40% |
| Pharmosa Biopharm Inc.TPEX: 6875 | $109.08M | NT$27.00 | -9.70% |
| Immunic, Inc.NasdaqCM: IMUX | $108.47M | $6.94 | -12.77% |
| Humacyte, Inc.NasdaqGS: HUMA | $108.23M | $0.36 | -6.49% |
| Tenax Therapeutics, Inc.NasdaqCM: TENX | $107.12M | $1.65 | -12.03% |
Figures last refreshed Oct 11, 2026.